ImCheck Therapeutics
Magali Colazet has a diverse work experience. Magali started their career as an Intern at IRD/CNRS in 2012, where they gained skills in molecular biology and worked on a project to generate genomic libraries for sequencing. In 2013, they interned at MedImmune, where they focused on the generation of stable monomeric IgG4 Fc fragments using phage display.
From 2013 to 2016, Magali worked as a PhD student at INSERM U1068 and Innate Pharma, where they specialized in antibody therapeutics and immunotargeting. Their PhD project involved generating nanobodies for immunotherapy applications, including library construction, phage display selection, production, purification, and screening.
Most recently, Magali worked as an R&D Scientist at Imcheck Therapeutics since December 2017, although the end date is unknown. Overall, Magali has developed expertise in various techniques related to molecular biology, cell culture, library construction, phage display, and antibody production and characterization.
Magali Colazet obtained a Two years University Diploma in Biochemistry from Aix-Marseille University in 2010. Magali then pursued a Master's degree in Biotechnology at Polytech Marseille - ESIL from 2010 to 2013. In terms of additional certifications, they obtained a TOEIC score of 965/990 from the University of Cambridge in October 2019. Magali also completed a Healthcare Finance course from MITx on edX in May 2019. Furthermore, they earned an attestation for the MOOC Gestion de Projet session 15 Parcours Classique from MOOC Gestion de Projet in May 2020.
ImCheck Therapeutics
1 followers
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.